[1]Jemal A,Bray F,Center MM,et al.Global cancer statistics[J].CA Cancer J Clin,2011,61(2):69-90.
[2]Hernandez-Gea V,Toffanin S,Friedman SL,et al.Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma[J].Gastroenterology,2013,144(3):512-527.
[3]Chen CJ,Lee MH.Early diagnosis of hepatocellular carcinoma by multiple microRNAs:validity,efficacy,and cost-effectiveness[J].J Clin Oncol,2011,29(36):4745-4747.
[4]Peck-Radosavljevic M.Drug therapy for advanced-stage liver cancer[J].Liver Cancer,2014,3(2):125-131.
[5]江敏.氨基葡萄糖的药理学研究进展[J].中国药房,2010,21(17):1622-1624.
[6]Dahmer S,Schiller RM.Glucosamine[J].Am Fam Physician,2008,78(4):471-476.
[7]Ju Y,Yu A,Sun X,et al.Glucosamine,a naturally occurring amino monosaccharide,inhibits A549 and H446 cell proliferation by blocking G1/S transition[J].Mol Med Rep,2013,8(3):794-798.
[8]Chesnokov V,Sun C,Itakura K.Glucosamine suppresses proliferation of human prostate carcinoma DU145 cells through inhibition of STAT3 signaling[J].Cancer Cell International,2009,9(1):25.
[9]Zhang L,Liu WS,Han BQ,et al.Antitumor activities of D-glucosamine and its derivatives[J].J Zhejiang Univ Sci B,2006,7(8):608-614.
[10]Wang Z,Liang R,Huang GS,et al.Glucosamine sulfate-induced apoptosis in chronic myelogenous leukemia K562 cells is associated with translocation of cathepsin D and downregulation of Bcl-xL[J].Apoptosis,2006,11(10):1851-1860.
[11]Song KH,Kang JH,Woo JK,et al.The novel IGF-IR/Akt-dependent anticancer activities of glucosamine[J].BMC Cancer,2014,14:31.
[12]蒋成英,戴广海.Ras Raf Mek Erk信号传导通路在肝细胞癌发生中的作用机制及在靶向治疗中的应用[J].中国肿瘤临床,2008,35(23):1377-1380.
[13]Lin ZH,Wang L,Zhang JB,et al.MST4 promotes hepatocellular carcinoma epithelial-mesenchymal transition and metastasis via activation of the p-ERK pathway[J].Int J Oncol,2014,45(2):629-640.
[14]Zhao LY,Zhang J,Guo B,et al.MECP2 promotes cell proliferation by activating ERK1/2 and inhibiting p38 activity in human hepatocellular carcinoma HEPG2 cells[J].Cell Mol Biol(Noisy-le-grand),2013,Suppl 59:L1876-L1881.
[15]Hsu FT,Liu YC,Chiang IT,et al.Sorafenib increases efficacy of vorinostat against human hepatocellular carcinoma through transduction inhibition of vorinostat-induced ERK/NF-kappaB signaling[J].Int J Oncol,2014,45(1):177-188.
[16]Fan C,Zheng W,Fu X,et al.Strategy to enhance the therapeutic effect of doxorubicin in human hepatocellular carcinoma by selenocystine,a synergistic agent that regulates the ROS-mediated signaling[J].Oncotarget,2014,5(9):2853-2863.